Brought to you by 
Genzyme acquires Bone Care International for $600mm
30 Jun 2005
Executive Summary
Genzyme has acquired Bone Care International (vitamin D-hormone therapy for serious diseases) for $33 per share, which equates to about $600mm in cash. The purchase price, which is net of Bone Care's $119mm cash and cash equivalents that it will return to Genzyme, is almost 14 times Bone Care's 2004 revenues, and represents a 34% premium to the company's trading average.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme acquires Bone Care International for $600mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice